<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744403</url>
  </required_header>
  <id_info>
    <org_study_id>CS1001-102</org_study_id>
    <nct_id>NCT03744403</nct_id>
  </id_info>
  <brief_title>A Study of CS1001 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study of an Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety,
      tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced
      solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From first dose to 90 days after last dose of CS1001, up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CS1001 monoclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1001</intervention_name>
    <description>In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.</description>
    <arm_group_label>CS1001 monoclonal antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with metastatic or locally advanced unresectable solid tumor, who progressed
             following treatment with all available standard therapy, or for whom treatment is not
             available, not tolerated or refused.

          2. ECOG performance status of 0 or 1.

          3. Subjects must have at least one measurable lesion.

          4. Patients with life expectancy ≥ 3 months.

          5. Subject must have adequate organ function.

          6. Fertile men and women of childbearing potential must agree to use an effective method
             of birth control from providing signed consent and for 180 days after last study drug
             administration.

        Exclusion Criteria:

          1. Known brain metastasis or other CNS metastasis that is either symptomatic or
             untreated.

          2. Subjects with active autoimmune diseases or history of autoimmune diseases should be
             excluded.

          3. Patients who have received prior therapies targeting PD-1, PD-L1, or CTLA-4.

          4. Known history of HIV infection.

          5. Subjects with active Hepatitis B or C infection.

          6. Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the
             exception of vitiligo, alopecia.

          7. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have
             history of uncontrolled allergic asthma.

          8. Known history of alcoholism or drugs abuse.

          9. Subjects who received organ transplantation.

         10. Known psychiatric disorders that would interfere with cooperation with the
             requirements of the trial.

         11. Female subjects who are pregnant or breast-feeding; Male or female subjects of
             childbearing potential who refuse to use an effective method of birth control.

        For more information regarding trial participation, please contact at
        cstonera@cstonepharma.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>+86 21 61097678</phone>
    <phone_ext>8118</phone_ext>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Tolcher</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

